Ophthalmology

Top Story

AKB-9778 improves underlying diabetic retinopathy in TIME-2 study

February 11, 2016

AKB-9778 alone or in combination with ranibizumab improved underlying diabetic retinopathy in eyes with and without diabetic macular edema in the TIME-2 phase 2a study, Aerpio Therapeutics announced in a press release.

Patients in the TIME-2 study were administered 15 mg of AKB-9778 alone, 15 mg of AKB-9778 in combination with 0.3 mg of Lucentis (ranibizumab, Genentech) or 0.3 mg of ranibizumab alone.

Breaking News

Doctors urge Congress to preserve the 340B Drug Pricing Program

February 11, 2016
Thousands of physicians from American safety-net hospitals signed a letter sent to Congress highlighting the importance of the 340B Drug Pricing Program.The letter asks…
Meeting News Coverage

Reading speed suitable outcome measure for lampalizumab trials

February 11, 2016
MIAMI — Results of the MAHALO study support the use of reading speed as a secondary outcome measure in clinical trials for lampalizumab, a speaker told colleagues…
In the Journals

Vision-threatening abnormalities possible in infants with presumed Zika virus-associated microcephaly

February 10, 2016
Infants who are born with microcephaly due to congenital infection from presumed exposure to the Zika virus may have vision-threatening abnormalities, according to a…
Meeting News Coverage

Anti-VEGF with targeted retinal photocoagulation does not reduce treatment burden for DME patients

February 10, 2016
MIAMI — Anti-VEGF injections in combination with targeted retinal photocoagulation did not show a decrease in treatment burden in patients with diabetic macular…
More News Headlines »
Practical Retina

Comparing Aflibercept, Bevacizumab, and Ranibizumab for DME: Analysis of DRCR Protocol T

Ophthalmic Surgery, Lasers and Imaging Retina, March 2015, Volume 46 Issue 3
More »
CME

Avoiding “Loss of Chance”… Improving the Screening, Treatment, and Referral of Patients with Diabetic Retinopathy

This activity is supported by an educational grant from Genentech, Inc.

Despite a number of effective treatment options, diabetic eye disease is a leading cause of vision loss in the United…
More »
Featured
Video

VIDEO: Surgeon prefers fourth-generation fluoroquinolones as prophylaxis for cataract surgery

February 3, 2016
More »
morganatic-roan